(Reuters Health) – Aligning with heart health groups and other experts, a U.S. government-backed panel now suggests that adults as young as 40 without a previous heart attack or stroke may need to start on a low or moderate dose of cholesterol-lowering drugs.
Doctors may also consider prescribing the drugs for people in this age group with a 7
People ages 40 to 75 with at least one risk factor for cardiovascular disease and a 10 percent or greater risk of heart attack or stroke over the next decade should take statin drugs, the U.S. Preventive Services Task Force recommends.
5 percent to 10 percent risk of heart attack or stroke based on the American Heart Association and American College of Cardiology risk calculator (cvriskcalculator).
“In addition to a healthy lifestyle, statins are useful for people at an elevated risk for cardiovascular disease,” said Dr. Douglas Owens, of Stanford University in California and a member of the USPSTF.
Risk factors for cardiovascular disease include high total cholesterol or triglycerides – known as dyslipidemia, high blood pressure, diabetes and smoking.
Cholesterol, a type of fat in the blood, can build up in arteries and increase the risk of heart attacks, strokes and other cardiovascular problems. Statins lower cholesterol by blocking its production in the liver.
This is the first time the USPSTF is making a recommendation on the use of statins. It’s based on analysis of existing data from 18 randomized controlled trials comparing statin use among people without previous heart attacks and strokes to people taking dummy pills or nothing at all.
Compared to those who are not on treatment, statin use was tied to a 17 percent reduced risk of death from any cause, and a 36 percent reduced risk of death from cardiovascular disease.
Ten-year risk of heart attack and stroke is calculated based on these and additional factors like sex and ancestry
People taking statins were also 28 percent less likely to have strokes, 37 percent less likely to have heart attacks and 31 percent less likely to have other cardiovascular problems.
The benefits of statins were consistent in people with different risk factors, the panel found. And serious side effects like muscle or liver problems and diabetes were not significantly increased according to the analysis.
The new recommendation isn’t surprising and is consistent with 2013 recommendations from the American Heart Association and American College of Cardiology, according to Dr. Sekar Kathiresan, who wasn’t involved with the new recommendation but is director of preventive cardiology at Massachusetts General Hospital in Boston.
Those organizations recommended statins for people ages 40 to 75 with diabetes or a 7.5 percent or greater risk of heart attack or stroke over the next decade, people with a previous heart attack or stroke and young people with very high LDL (“bad”) cholesterol.
In another recommendation published online on Monday, the USPSTF proposed an update to its advice on testing children and teens for dyslipidemia, that is, high cholesterol level from any cause, including the inherited condition known as familial high cholesterol.
As it had in 2007, the panel said there is still not enough evidence to recommend for or against screening people younger than age 20 for either high cholesterol in general, which affects roughly seven of every 100 children and teens in the U.S., or familial hypercholesterolemia, which affects one in every 200 to 500 people across North America and Europe.
The statement is in line with the advice of the UK National Screening Committee and the American Academy of Family Physicians.
“We’d say if you have concerns or any concern of elevated risk, it would be time to have a conversation with a child’s clinician,” he said.
The panel also points out that the American Academy or Pediatrics (AAP) and the National Heart, Lung, and Blood Institute endorse universal screening for all children before ages nine and 11, and again between puberty and adulthood. Earlier testing is recommended for children at an increased risk of the condition.
“I actually tend to err on the side of AAP here, because it’s quite common and treatable,” Kathiresan told Reuters Health.
“I think it’s appropriate for a national body to say we don’t have definitive evidence,” he said, but he added that the problem is that finding the condition when a person is young is an incredible opportunity to modify risks in those people.